APA
CTIC

American Portfolios Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

American Portfolios Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10
Closed -$16 – 2984
2019
Q4 		$16 Hold
10
– – ﹤0.01% 2832
2019
Q3 		$8 Hold
10
– – ﹤0.01% 2827
2019
Q2 		$9 Hold
10
– – ﹤0.01% 2724
2019
Q1 		$10 Hold
10
– – ﹤0.01% 2609
2018
Q4 		$7 Buy
+10
New +$16 ﹤0.01% 2395

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

American Portfolios Advisors's CTIC Position: Q1 2020 in Review

American Portfolios Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2020, closing a stake of 10 shares — an estimated $16 sold.

American Portfolios Advisors first reported a position in CTIC in Q4 2018 and held it in 5 quarters. The position peaked at $16 in Q4 2019. 38 funds tracked by Wall St. Rank hold CTIC as of Q1 2020.

  • American Portfolios Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2020 after selling out during the quarter.
  • American Portfolios Advisors sold 10 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2020, an estimated $16.
  • American Portfolios Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2018 and held it in 5 quarters.
  • American Portfolios Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $16 in Q4 2019.
  • 38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2020.

Based on American Portfolios Advisors's 13F filing for Q1 2020, filed 24 Mar 2023.